About Medytox Venture
Medytox Venture is a venture capital firm founded in 2017. It is primarily based out of Seoul, South Korea. As of Oct 2024, Medytox Venture has invested in 4 companies. It primarily invests in Series A round in South Korea based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Series A round of AIGEN Sciences A lot of funds co-invest with Medytox Venture, with names like QUAD sharing a substantial percentage of its portfolio. Medytox Venture has team of 6 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A & Series B
Medytox Venture's List of All Investments
Medytox Venture has a portfolio of 4 companies. Their most notable investmentis in ZymediTheir portfolio spans across and South Korea. They have invested in Life Sciences, Enterprise Applications, High Tech and 1 other sectors, across stages such as Series A, Series B stages. Here is the list of all investments by Medytox Venture:
AI-based drug discovery and designing tool for researchers. The company has developed a proprietary tool AIGEN Discovery that assists with the discovery and designing of new drugs. The system can be used for drug targeting, data analysis, novel compounds optimization, and more.
Key facts about AIGEN Sciences
- Founded Year: 2021
- Location: Seoul (South Korea)
- Stage: Series A
- Total Funding till date: $8.81M
- Investors: Partners Investment, QUAD and 5 Others
- Latest Funding Round: Series A, Jul 11, 2025, $*****
- Highlight: Editors' Pick
2. Neocannbio
Developer of cannabinoid ingredients and natural products for pharmaceutical applications. It focuses on developing new drugs using intelligent drug delivery systems. The company is building a cannabinoid library for discovering new efficacies. It develops GMP production processes for high-purity cannabidiol using microwave processing technology. The company also develops technology for mass production and commercialization of medical cannabinoids.
Key facts about Neocannbio
- Founded Year: 2021
- Location: Seoul (South Korea)
- Stage: Series B
- Total Funding till date: $10.9M
- Investors: QUAD, Bilanx and 16 Others
- Latest Funding Round: Series B, Sep 26, 2023, $*****
- Highlight: Editors' Pick
Developer of biomarker-driven anti-cancer targeted therapies. The company is developing targeted, biomarker-driven onco-therapeutics focused on the areas of cell cycle regulation, DNA damage response, and undruggable cancer targets. It is primarily based on the concept of synthetic lethality called “SMILO" (Small Molecules Inducing Lethality in Oncogenic cells) that targets specific inhibitors.
Key facts about Avelos Therapeutics
- Founded Year: 2021
- Location: Gangseo (South Korea)
- Stage: Series B
- Total Funding till date: $20.5M
- Investors: Timefolio Capital, Mirae Asset and 11 Others
- Latest Funding Round: Series B, Apr 30, 2024, $*****
- Highlight: Editors' Pick
4. Zymedi
Developer of therapeutics for multiple diseases. It offers Aminoacyl-tRNA Synthetase-based drugs which include ZM-A001 for Pulmonary arterial hypertension, ZM-C001 for NASH (Non-alcoholic steatohepatitis), and ZM-C101 for colorectal cancer.
Key facts about Zymedi
- Founded Year: 2019
- Location: Incheon (South Korea)
- Stage: Series A
- Total Funding till date: $29.5M
- Investors: Company K Partners, KVIC and 6 Others
- Latest Funding Round: Series A, May 30, 2023, $*****
- Highlight: Editors' Pick
Medytox Venture's Year-on-Year Investment Trends
Medytox Venture has invested in 4 companies over the last 3 years, with an average of 1 new investment annually in the last 3 years. Its most recent first time investment was in AIGEN Sciences.Medytox Venture's Investments by Stage
Medytox Venture has made 2 investments in Series A stage with an average round size of $10.4M and 2 investments in Series B stage with an average round size of $9.96M.Stage of entry | No. of Investments |
|---|---|
Series A | 2 |
Series B | 2 |
Note: We have considered here, only first round of investments
Medytox Venture's Investments by Sector
Medytox Venture has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Artificial Intelligence - Industry Applications, Enterprise Applications and High Tech. Notably, it has invested in 4 Enterprise (B2B) companies, 4 Tech companies, 2 Software companies and at least 1 company focusing on AI-Native.Sector | No. of Investments |
|---|---|
Life Sciences | 3 |
HealthTech | 2 |
Artificial Intelligence - Industry Applications | 1 |
Enterprise Applications | 1 |
High Tech | 1 |
Note: We have considered here, only first round of investments
Medytox Venture's Investments by Geography
Medytox Venture has made most investments in South Korea (4).Medytox Venture's recent investments
Medytox Venture has not made any investment in 2026 so far.Here are the most recent investments by Medytox Venture:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 16, 2024 | South Korea | Series A | 8720 | [+4] | |
Apr 30, 2024 | South Korea | Series B | 3594 | [+7] | |
Sep 26, 2023 | South Korea | Series B | 3522 | [+4] | |
May 30, 2023 | South Korea | Series A | 9123 | [+5] |
Team profile of Medytox Venture
Medytox Venture has a team of 6 members including 2 Partners and 1 Principal located in South Korea. Medytox Venture's team does not sit on the board of any company as of now.Here is a list of all team members in Medytox Venture:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | - | - | - | |
Partner | - | - | - | |
Principal | Seoul | - | - |
Co-investors of Medytox Venture
Over the past 3 years, 30 investors have co-invested in Medytox Venture's portfolio companies. This includes funds and angels.
- Invested before Medytox Venture: KT&G, Medytox and 8 others have invested in rounds before Medytox Venture. There is 1 company where KT&G has invested before Medytox Venture and 1 company where Medytox has invested before Medytox Venture.
- Top Co-investors of Medytox Venture: 19 investors entered a company along with Medytox Venture. These include investors like QUAD (2 companies).
- Invested after Medytox Venture: Hyosung Ventures (1 company) is the only investor which has invested in Medytox Venture's portfolio after their investments.
Recent News related to Medytox Venture
•
AI drug developer Aigen Sciences raises ₩12B series ABioWorld•Oct 30, 2024•AIGEN Sciences, Partners Capital, QUAD, Medytox Venture and 3 others
•
Avelos therapeutics announces krw 17 billion series b funding round, surpassing krw 30 billion total raisedPR Newswire•May 29, 2024•Avelos Therapeutics, Stassets Investment, LSK investment, Medytox Venture and 7 others
•
Selecxine attracts USD 12 million series A. after developing “IL-2·TCB2 conjugate”Selecxine•Jul 05, 2020•Selecxine, Sj Invest Online, Stonebridge Ventures, POSCO Investment and 4 others
